Drug intelligence / Profile preview

CLXR-003

Development stage: Preclinical
Lead developer: Cardiogeni
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Epicardial

Overview

CLXR-003 is a preclinical cell therapy candidate developed by Cardiogeni for the treatment of early-stage heart failure. The therapy utilizes induced Myogenic Progenitor (iMP) cells, which are delivered directly to the epicardium via a specialized patch. This approach aims to regenerate damaged cardiac tissue and improve heart function by providing a localized and sustained source of regenerative cells, potentially bypassing the limitations of systemic or direct intramyocardial injection. The iMP cells are designed to integrate into the myocardium and facilitate tissue repair, addressing the underlying structural damage associated with heart failure.

Other names: iMP cell therapy patch

Beyond the preview

Go deeper on CLXR-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLXR-003.

Explore the full profile